Are cardiovascular risk factors also associated with the incidence of atrial brillation? A systematic review and eld synopsis of 23 factors in 32 population- based cohorts of 20 million participants. Thromb Haemost. 2017;117(5):837-850. 19. Moran PS, Teljeur C, Ryan M, Smith SM. Systematic screening for the detection of atrial brillation. Cochrane Database Syst Rev. 2016;(6):CD009586. 20. Amerena J, Chen SA, Sriratanasathavorn C, et al. Insights into management of atrial brillation in Asia Paci c gained from baseline data from REgistry on cardiac rhythm disORDers (RecordAF-Asia Paci c [AP]) registry. Am J Cardiol. 2012;109(3): 378-382. 21. Oldgren J, Healey JS, Ezekowitz M, et al. Variations in cause and management of atrial brillation in a prospective registry of 15,400 emergency department patients in 46 countries: the RE-LY Atrial Fibrillation Registry. Circulation. 2014;129(15):1568-1576. 22. Oh S, Goto S, Accetta G, et al. Vitamin K antagonist control in patients with atrial brillation in Asia compared with other regions of the world: Real-world data from the GARFIELD-AF registry. Int J Cardiol. 2016;223:543-547. 23. J-RHYTHM Registry Investigators. Determinants of warfarin use and international normalized ratio levels in atrial brillation patients in Japan. Subanalysis of the J-RHYTHM Registry. Circ J. 2011;75(10):2357-2362. 24. Akao M, Chun YH, Wada H, et al. Current status of clinical background of patients with atrial brillation in a community- based survey: the Fushimi AF Registry. J Cardiol. 2013;61(4):260- 266. 25. Guo Y, Apostolakis S, Blann AD, et al. Validation of contemporary stroke and bleeding risk strati cation scores in non-anticoagulated Chinese patients with atrial brillation. Int J Cardiol. 2013;168(2): 904-909. 26. Xia S-j, Du X, Li C, et al. Uptake of evidence-based statin therapy among atrial brillation patients in China: a report from the CAFR (Chinese Atrial Fibrillation Registry) Study. Int J Cardiol. 2016;220: 284-289. 27. 